Zavain Dar

Board Director at Recursion Pharmaceuticals

Zavain is enthralled by the power of data and its counterpart, intelligence. He invests in companies that are using machine learning and AI to augment or replace physical-world functions including biology, language, manufacturing and analysis.

Zavain has led Lux’s investments in Primer, a stealth machine intelligence startup; Clarifai, which combines machine intelligence and image recognition; Capella, which is developing novel medicines based on computational insight applied to genomic data; Recursion which uses automation and deep learning to develop drugs for rare diseases; and Tempo Automation, which applies software and automation to electronics manufacturing.

Previously Zavain was an investor at Eric Schmidt’s Innovation Endeavors. There he sourced and led the firm’s investments in early-stage technology companies including Zymergen and BlockStream. Zavain drafted the firm’s theses in Genetics, Synthetic Biology and the Blockchain.

Before VC, Zavain was a founder and computer scientist. At Discovery Engine (acquired by Twitter), he engineered machine learning and AI systems across a proprietary distributed computing framework to build web scale-ranking algorithms. Zavain was also a co-founder of Fountainhop, one of the first hyper-local social networks.

Zavain holds a bachelor's degree in symbolic systems and a master's degree in computer science from Stanford where he was a researcher in Stanford’s AI Lab. He is currently a Lecturer at Stanford and has taught quarter-long seminars in Cryptocurrencies, Artificial Intelligence and Philosophy and Venture Capital.

Location

New York, United States

Links


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Recursion Pharmaceuticals

13 followers

Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease.